PCSK9 Antibody

Western blot: 1:1000

Titration of the PCSK9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Antigen affinity purified

In 1X PBS, pH 7.4, with 0.09% sodium azide

This PCSK9 antibody was produced from a rabbit immunized with a KLH conjugated synthetic peptide between 654-688 amino acids from the C-terminal region of human PCSK9.

This PCSK9 antibody is available for research use only.

Antigen affinity

Human

Q8NBP7